U.S. Markets closed

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
296.81+1.09 (+0.37%)
At close: 4:00PM EDT

296.81 0.00 (0.00%)
After hours: 4:57PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close295.72
Open299.24
Bid296.32 x 1000
Ask297.01 x 900
Day's Range296.37 - 303.60
52 Week Range151.47 - 387.40
Volume164,589
Avg. Volume340,191
Market Cap13.437B
Beta (5Y Monthly)1.31
PE Ratio (TTM)60.08
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin
    Business Wire

    Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin

    Abiomed announces record revenue of $241 million , up 17% year over year, with 26.0% operating margin.

  • ACCESSWIRE

    ABIOMED, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 29, 2021 / ABIOMED, Inc. (NASDAQ:ABMD) will be discussing their earnings results in their 2021 Fourth Quarter Earnings call to be held on April 29, 2021 at 8:00 AM Eastern Time.

  • Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella
    Business Wire

    Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella

    The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI). The study evaluated the outcomes of 406 consecutive patients who presented with acute myocardial infarction cardiogenic shock (AMICS) at 80 participating sites throughout the United States. The study shows a protocol-based approach to increasing survival rates in cardiogenic shock is reproducible in both academic and community hospital settings. Results were presented today by Babar Basir, DO, director of the acute mechanical circulatory support program at Henry Ford Hospital and co-principal investigator of the study, at the 2021 Society of Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions.